Universität zu Köln

Koleczko, S. and Wolf, J. (2020). Immune checkpoint inhibitors in lung cancer. Internist, 61 (7). S. 676 - 682. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Full text not available from this repository.

Abstract

Immune checkpoint inhibitors (ICI) have emerged as an important treatment strategy in lung cancer in recent years. Implementation and approval status of each approved ICI will be presented by summarizing the most important phase III studies of nivolumab, pembrolizumab, atezolizumab and durvalumab. ICI are used as mono- or combination therapy with chemotherapy according to programmed cell death 1 ligand 1 (PD-L1) status and therapy line.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Koleczko, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wolf, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-328429
DOI:	10.1007/s00108-020-00815-y
Journal or Publication Title:	Internist
Volume:	61
Number:	7
Page Range:	S. 676 - 682
Date:	2020
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1432-1289
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language SQUAMOUS-CELL; OPEN-LABEL; NIVOLUMAB; DOCETAXEL; CHEMOTHERAPY; MULTICENTER; IPILIMUMAB Multiple languages Medicine, General & Internal Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/32842